Mustang Bio is a clinical-stage biopharmaceutical company based in Worcester, Massachusetts, focused on cell and gene therapies for cancers and genetic diseases, with partnerships for CAR-T and XSCID treatments. The company went public on August 22, 2017, and has 80 employees.
Mustang Bio (MBIO) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Mustang Bio's actual EPS was -$37.95, missing the estimate of -$8.16 per share, resulting in a -365.07% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
